Welcome to the website for In re ImmunityBio Inc. Securities Litigation, pending in the United States District Court for the Southern District of California (the “Court”).
The purpose of this website is to inform you of the pendency of this class action (the “Action”) between Lead Plaintiff Dipak Patel on behalf of himself and all others similarly situated, and the Defendants ImmunityBio, Inc. (“ImmunityBio”), Richard Adcock, David C. Sachs, and Patrick Soon-Shiong.
If you purchased or acquired ImmunityBio, Inc. (“ImmunityBio”) (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, both dates inclusive (the “Settlement Class Period”), you could be entitled to a payment from a proposed class action settlement.
Please be advised that your rights may be affected by the above-captioned securities class action (the “Action”) pending in the United States District Court for the Southern District of California (the “Court”), if, during the period from March 10, 2021, and May 10, 2023, inclusive (the “Settlement Class Period”), you purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio”) (NASDAQ: IBRX) securities and were allegedly damaged thereby.
Please also be advised that the Court-appointed Lead Plaintiff Dipak Patel (“Lead Plaintiff”), on behalf of himself and the Settlement Class have reached a proposed settlement of the Action for $10,500,000.00 in cash that, if approved, will resolve all claims in the Action (the “Settlement”).
Please read the Notice to fully understand your rights and options. The Frequently Asked Questions page of this website has more information on your rights as a Class Member in this Action.
The Court has not decided whether Defendants did anything wrong, and the Notice is not an admission by Defendants or an expression of any opinion of the Court concerning the merits of the Action.